💊 SGLT2 Inhibitors: How They Work, Benefits for Heart & Kidney, and Risks

In recent years, one class of diabetes medications has risen to the top of treatment guidelines — not just for lowering blood sugar, but for its remarkable ability to protect the heart and kidneys. These are the SGLT2 inhibitors (sodium‑glucose cotransporter‑2 inhibitors). Drugs like dapagliflozin and empagliflozin have changed the game for people with Type 2 diabetes, especially those with heart failure or chronic kidney disease. Dr. Ravi Sishir Reddy explains how they work, why they’re so beneficial, and what important risks you must know about.

1. What Are SGLT2 Inhibitors?

SGLT2 inhibitors are oral medications that work on the kidneys — not the pancreas or the liver. In a healthy kidney, almost all of the glucose filtered from the blood is reabsorbed back into the bloodstream by a protein called SGLT2, so that precious energy is not lost in the urine. In diabetes, this mechanism works too well, keeping blood sugar high. SGLT2 inhibitors block this reabsorption, causing excess glucose to be excreted in the urine. This lowers blood sugar, but it also leads to calorie loss — which contributes to the weight loss often seen with these drugs.

Commonly prescribed SGLT2 inhibitors include:

• Dapagliflozin (Forxiga / Farxiga)
• Empagliflozin (Jardiance)
• Canagliflozin (Invokana)
• Remogliflozin (in India)

2. The Game‑Changing Benefits: Heart, Kidneys, and Weight

SGLT2 inhibitors are unique because they provide protection that goes far beyond lowering HbA1c. Major clinical trials have shown the following benefits consistently:

• Reduction in hospitalisation for heart failure: By around 30‑35%, even in people without diabetes. They are now a pillar of treatment for heart failure with reduced ejection fraction (HFrEF), independent of glucose levels.
• Slowing of chronic kidney disease (CKD): They reduce the decline in eGFR, lower protein in the urine (albuminuria), and delay the need for dialysis by 30‑40% in people with diabetic and non‑diabetic kidney disease.
• Weight loss: Typically 2‑4 kg of sustained weight loss, due to the calorie loss from urinary glucose excretion.
• Modest reduction in blood pressure: The osmotic diuretic effect lowers systolic BP by about 3‑5 mmHg.
• Reduction in cardiovascular death: Demonstrated in people with Type 2 diabetes and established cardiovascular disease.

Because of these benefits, SGLT2 inhibitors are now recommended as first‑line therapy alongside metformin (or even without metformin) in patients with heart failure, CKD, or high cardiovascular risk, regardless of the baseline HbA1c.

3. Important Side Effects and Risks to Know

While SGLT2 inhibitors are generally safe and well‑tolerated, they do have a unique set of potential side effects that patients must be aware of:

• Genital and urinary tract infections: Because there is glucose in the urine, the risk of fungal (thrush) infections in the genital area and bacterial urinary tract infections increases. Good personal hygiene, wiping front to back, and staying hydrated can help. Most infections are mild and treatable.
• Dehydration and orthostatic hypotension: The increased urination can lead to volume depletion, especially in older adults or those on diuretics. Symptoms include dizziness upon standing, dry mouth, and dark urine. Staying well hydrated is important.
• Euglycemic diabetic ketoacidosis (DKA): This is a rare but dangerous side effect. In a small number of patients, SGLT2 inhibitors can trigger DKA — a buildup of acid (ketones) in the blood — even when blood sugar levels are not very high (euglycemic = "normal sugar"). Triggers include illness, surgery, prolonged fasting, very low‑carb diets, and excessive alcohol. Symptoms include nausea, vomiting, abdominal pain, deep rapid breathing, and confusion. If DKA is suspected, stop the medication and seek emergency care immediately.
• Increased risk of amputation and fractures: Canagliflozin has been specifically associated with a higher risk of lower‑limb amputations and bone fractures. This has not been seen with empagliflozin or dapagliflozin. Dr. Reddy notes that canagliflozin is now less commonly used for this reason.
• Fournier's gangrene: An extremely rare but severe infection of the perineum and genital area. Any sudden pain, redness, swelling, or fever in the genital or anal area should be evaluated urgently.

4. Who Should NOT Take SGLT2 Inhibitors?

• Type 1 diabetes: The risk of DKA is significantly higher; these drugs are generally not recommended in Type 1 except in very specialised research settings.
• Severe kidney impairment: They are less effective when eGFR is very low (below 20‑25 mL/min depending on the specific drug) and may not be started in those ranges, though they may still have kidney‑protective effects.
• Pregnancy and breastfeeding: Safety has not been established; insulin is used instead.
• History of frequent genital infections or poor personal hygiene may make these drugs less desirable.
• Patients on very low‑carb or ketogenic diets should use SGLT2 inhibitors only under close medical supervision due to the risk of DKA.

5. Practical Tips for Taking an SGLT2 Inhibitor

• Take once daily: With or without food, usually in the morning. Do not double‑dose if you miss one.
• Stay well hydrated: Aim for 2‑3 litres of water per day to reduce the risk of dehydration and infections.
• Practice good genital hygiene: Shower daily, wear cotton undergarments, and change out of wet clothing promptly.
• Monitor for DKA symptoms: If you are unwell, vomiting, or unable to eat, temporarily stop the medication and seek medical advice. Do not restart until you have recovered and are eating normally.
• Inform all healthcare providers that you are taking an SGLT2 inhibitor, especially before any surgery. These drugs are usually stopped 2‑3 days before elective procedures.